Global Influenza Vaccine Market 2018-2022
About Influenza Vaccine
Influenza is an infectious disease caused by the influenza virus. It is also known as flu. Influenza virus is a ribonucleic acid (RNA) virus that belongs to Orthomyxoviridae family. It is a helical shaped, single-stranded virus. Influenza A virus affects people of all age groups and causes moderate to severe illness, while the infection due to influenza B virus results in milder disease and affects pediatrics primarily. Human illness due to influenza C is rare. Influenza C illness might be due to subclinical cases. Hence, it does not cause epidemic diseases. Influenza has emerged as a severe health concern globally. The market encompasses both live attenuated as well as recombinant influenza vaccines for the prevention of influenza. The major factors that lead to the market growth include the need for annual vaccination and government initiatives to improve awareness about vaccination.
Technavio’s analysts forecast the global influenza vaccine market to grow at a CAGR of 7.23% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global influenza vaccine market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of influenza vaccine.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Influenza Vaccine Market 2018-2022
Technavio recognizes the following companies as the key players in the global influenza vaccine market: AstraZeneca, CSL, GlaxoSmithKline, and Sanofi.
Other Prominent Vendors in the market are: Altimmune, BionVax, FluGen, FOLIA BIOTECH, Genentech, Green Cross, Medicago, Moderna Therapeutics, Novavax, Shijiazhuang Yiling Pharmaceutical, SK Chemicals, UNM Pharma, Vaccitech, Vaxart, Vaxine Pty, and Visterra.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is development of strong pipeline. The increasing R&D programs is significantly influencing the growth of the pipeline molecule count in the influenza market. Universal influenza vaccine initiative (UIVI) is a program conducted to combat the challenges in developing a vaccine that broadly protects against all types of influenza viruses. Furthermore, the number of clinical trials for developing a vaccvine for treating influenza is steadily increasing. The launch of all molecules in phase III will generate significant revenue on completion of the clinical trials.”
According to the report, one of the major drivers for this market is rising awareness about influenza vaccination. With the growing support of both government and non-government bodies, the awareness about influenza virus is rising across the globe. Both the government and non-government organizations are taking adequate initiatives to prevent diseases. To educate people about the influenza virus and the importance of influenza vaccination, CDC conducts national vaccination week. WHO has developed generic campaign materials to support the campaign. Such initiatives will help people gain more knowledge about the preventive measures available against influenza, in turn, driving the demand for these vaccines.
AstraZeneca, CSL, GlaxoSmithKline, Sanofi, Altimmune, BionVax, FluGen, FOLIA BIOTECH, Genentech, Green Cross, Medicago, Moderna Therapeutics, Novavax, Shijiazhuang Yiling Pharmaceutical, SK Chemicals, UNM Pharma, Vaccitech, Vaxart, Vaxine Pty, and Visterra.